Navigation Links
Unilife Completes A$23.1 Million Private Placement
Date:12/3/2010

LEWISBERRY, Pa., Dec. 3, 2010 /PRNewswire-FirstCall/ -- Unilife Corporation (Unilife or Company) (Nasdaq: UNIS; ASX: UNS) announced today that it has completed the A$23.1 million private placement (Placement), which was previously announced on 29 November 2010.

Unilife issued 27,228,143 CHESS Depositary Interests (CDIs) (Placement CDIs) at an issue price of A$0.85 (each CDI representing an interest in one sixth of a share of the Company's common stock) with free attaching unlisted options (Placement Options) to sophisticated and professional investors in Australia. The principal terms of the Placement CDIs and Placement Options are as set out in our announcement on 29 November 2010.

Unilife intends to use the net proceeds from the Placement and SPP for the purchase of additional capital equipment, for general operations including the development of other pipeline products and supporting the 2011 transition of Unilife into a commercial manufacturer and supplier of its proprietary medical devices to pharmaceutical and healthcare companies.

As the issue of the Placement CDIs was within the Company's 15% issue capacity under ASX Listing Rule 7.1, approval for the issue of the Placement CDIs (and Placement Options) is not being sought from the Company's shareholders.

Restrictions on resale of shares and CDIs into the U.S.The Placement was, and the forthcoming Share Purchase Plan (SPP) will be, made available to investors in reliance on the exemption from registration contained in Regulation S of the United States Securities Act of 1933 (US Securities Act) for offers of securities which are made outside the U.S. This means that a registration statement (similar to an Australian prospectus) is not required to be prepared with respect to the Placement or the SPP.

However, in order t
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
2. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
3. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
4. Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe
5. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
6. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
7. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
8. Unilife Corporation Announces Financial Results for Fiscal Year 2011 First Quarter
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Conn. , Aug. 27, 2014  UBM Medica ... a leading online community for medical imaging professionals, presents ... Association for Medical Imaging Management,s 2014 Annual Meeting . ... conference coverage: , 11 Principles of ... can lead to greater profitability. , Why ...
(Date:8/27/2014)... 2014 Ambit Biosciences (Nasdaq: AMBI ), a ... unmet needs in oncology, autoimmune and inflammatory disease, today announced ... to be held at The New York Palace Hotel in ... 2014. Alan Fuhrman , Ambit,s CFO, will ... candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September 3, ...
(Date:8/27/2014)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... scheduled to make an investor presentation at the Robert W. ... on Wednesday, September 3, in New York City.  ... be available in the Investors section of the IRIDEX website ... IRIDEX Corporation was founded in 1989 and is a ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... December 13, 2011 -- Breadth of ... Pieris AG presented novel preclinical in ... its PRS-080 Anticalin hepcidin antagonist in an oral presentation ... company announced today.  In a presentation entitled "Discovery and ...
... 13, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: ... Ltd. announced that final results from the phase II ... or refractory acute myeloid leukemia (AML) were presented by ... Anderson Cancer Center during the Acute Myeloid Leukemia - ...
Cached Medicine Technology:Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 2Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... especially when your infant looks at you and babbles. ... by listening and responding, they let their infants know ... sounds and using language more quickly. , That,s according ... and Indiana University that found how parents respond to ... communicate and use vocalizations. , The findings challenge the ...
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... 27, 2014 The American Brain ... of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery ... the ABTA is seeding the field with talented, bright ... understanding of the causes, effects, diagnosis and treatment of ... scientific committee based on the potential to advance the ...
(Date:8/27/2014)... While many scientists are trying to prevent the ... autophagy, researchers at Virginia Commonwealth University Massey Cancer ... that causes the process to culminate in cell ... targets the p62 protein, which is often referred ... role in disposing unwanted cellular proteins during autophagy. ...
Breaking Medicine News(10 mins):Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Parents, listen next time your baby babbles 2Health News:Parents, listen next time your baby babbles 3Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2
... already known to predict heart disease may also indicate ... a new Johns Hopkins study. ,C-reactive protein, or ... of CRP have been linked to higher risks of ... and diabetes. Researshers hypothesized that inflammation could play a ...
... legs syndrome is an irritating feeling of uneasiness, tiredness and ... can be painful // and often worsen at night. ... called restless legs syndrome. Studies on restless legs syndrome are ... to look at the prevalence and factors related to restless ...
... source of radiation exposure to the general population. Although ... also believed exposure during the test is responsible for ... to calculate the risk of cancer from exposure to ... and Cancer Research in the United Kingdom conducted the ...
... blood may predict the risk of heart attack or death ... new study. ,Researchers conducted a study to determine whether ... for death or non-fatal heart attack in patients with acute ... factor family and it acts as an instigator of hardening ...
... cancer accounts for the largest number of new cancer ... an international study found the survival rate of non-small-cell ... adjuvant chemotherapy. Cisplatin is an anti-neoplastic medication that interferes ... growth and spread in the body. ,As ...
... percent of diabetics take the proper preventative measures ... Researchers stressed continued negligence by diabetics increases their ... coronary heart disease, stroke, and lower extremity amputations. ... years or older, who had been diagnosed with ...
Cached Medicine News:Health News:Blood Marker Found To Predict Colon Cancer 2
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: